Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > Taking it in the Chin
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by PROtradingon Oct 17, 2016 10:45am
39 Views
Post# 25350969

RE:RE:RE:RE:Taking it in the Chin

RE:RE:RE:RE:Taking it in the Chin
LaticelnExile wrote:
Dyrenium and Zonegram????    I don't thinks so.....  My bet is on the LU.  My data is Veritas data via Symphony.


See, that's why I'm in love with Latice.  Provide valuable information for anyone really intererest in pharma.  "Verita via Symphony"   But WTF is "LU"?

And what about Delerium?  That's the drug all these longs have been taking like crazy!?  Sales must be right through the FREAKING ROOF!!!! 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities